Neoadjuvant FOLFIRINOX Application in Borderline Resectable XXXX : A Retrospective Cohort Study.

@entity901 @entity4181 @entity788 @entity137 @entity2600 @entity1
5-Fluorouracile, @entity901 , @entity2600 , and @entity4181 (FOLFIRINOX) has not been extensively used in the neoadjuvant setting because of concerns with safety and @entity137 . We evaluated our institutional experience with neoadjuvant FOLFIRINOX in borderline resectable @entity788 (BRPAC). The primary endpoints were completion of therapy to surgery and negative resection margin (R0) rate. @entity1 with BRPAC treated with neoadjuvant FOLFIRINOX were retrospectively analyzed. Between August 2011 and September 2013, 20 @entity1 with BRPAC treated with neoadjuvant FOLFIRINOX were identified.Most @entity1 (88.8%) completed FOLFIRINOX therapy and underwent resection. Abutment of venous structures was identified in 13 cases (72.2%), while short segment portal vein encasement in 3 cases (16.6%) with concomitant arterial involvement in 3 cases (16.6%). Isolated superior mesenteric artery abutment was identified in 2 cases (11.2%). @entity1 received a median of 4 cycles of FOLFIRINOX. There was 1 case of progression. Vascular resection was performed in 9 cases (52.9%). Preoperative radiation therapy was used in 8 @entity1 (44%). All @entity1 underwent margin negative resection (R0). Histopathologic treatment response was evident in 10 cases (58.8%).Neoadjuvant FOLFIRINOX was generally safe and the expected @entity137 did not prevent surgery allowing for a high rate of R0 resection.
